Short- versus long-term Dual AntiPlatelet Therapy for Stent-Assisted treatment of CErebral aneurysm (DAPTS ACE): a multicenter, open-label, randomized clinical trial
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    The Ongoing Debate Over Dual Antiplatelet Therapy in Cerebral Aneurysm Treatment
    • Ali Mirshamsi, MD Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran

    Dear Editor,
    I am writing to address the significant findings presented in the article "Short- versus long-term Dual AntiPlatelet Therapy for Stent-Assisted treatment of CErebral aneurysm (DAPTS ACE)." This research, a randomized clinical trial aimed at unraveling the ideal duration of Dual AntiPlatelet Therapy (DAPT) after stent-assisted coil embolization (SACE) for cerebral aneurysms, raises crucial questions regarding the management of these delicate cases.
    The article reports that the trial, DAPTS ACE, investigated whether extending DAPT for 12 months could effectively reduce the risk of ischemic stroke in comparison to a shorter 3-month DAPT regimen for patients who underwent SACE for cerebral aneurysms. The study, conducted in 17 hospitals in Japan, enrolled 142 patients between November 4, 2016, and January 7, 2019, and assigned them randomly to either the long-term or short-term DAPT group. The primary outcome was the occurrence of ischemic stroke events during the period of 3 to 12 months after SACE.
    The results are undeniably important, as they indicate that there was no statistically significant difference in the rate of ischemic strokes between the long-term and short-term DAPT groups. In fact, ischemic stroke was a rare occurrence in both groups, and the data show that the extended duration of DAPT did not offer a significant advantage in preventing ischemic events. This is the first randomized controlled trial to tackle the duratio...

    Show More
    Conflict of Interest:
    None declared.